Resumen de Chapter Thirteen - Modulators of Atypical Protein Kinase C as Anticancer Agents
Jonathan R.A. Roffey, Gregory R. Ott
Abstract The atypical protein kinase C (PKC) isoforms (zeta and iota) have recently garnered attention as therapeutic targets for oncology, metabolic diseases as well as other indications. Though the novel and classical PKC isoforms have been interrogated as therapeutic intervention points and inhibitors of these isoforms (both selective and nonselective) have advanced to the clinic, no atypical inhibitor has been validated at this level. Recent biological studies have demonstrated the direct role for atypical PKC isoforms in specific cancers and the preclinical validity of atypical PKCs as therapeutic intervention points. This review will cover the structure/function of atypical PKCs versus novel and classical PKC isoforms, the implications in disease states, focusing on oncology, and a summary of both non-ATP competitive and ATP-competitive atypical PKC inhibitors.
